Computer-aided discovery of synergistic drug combinations with Remdevisir for COVID-19

COVID-19 Research Area(s): Vaccines & Treatments

Drug reprofiling (repurposing) implies the use of existing drugs approved for other indications, and yet showing useful activity against SAR-CoV-2 virus. One well-known example of this strategy is remdesivir, currently the most promising treatment against COVID-19, and which was originally developed as Hepatitis C drug. Although very promising, remdesivir is still modestly efficient against COVID-19 and hence, if one could further boost its effectiveness by using it in a synergetic combination with another reprofiled drug, the pandemic might finally see the resolution. This consortium of national and international scientists wants to identify such much-needed SARS-CoV-2 inhibitor among known drugs, which then will be used either as stand-alone therapy for COVID-19 or a synergetic 'booster' for remdesivir.